Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Identifieur interne : 002414 ( Ncbi/Merge ); précédent : 002413; suivant : 002415Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Auteurs : Laureline Legendre [France] ; Thomas Barnetche [France] ; Juliette Mazereeuw-Hautier [France] ; Nicolas Meyer [France] ; Dedee Murrell [Australie] ; Carle Paul [France]Source :
- Journal of the American Academy of Dermatology [ 1097-6787 ] ; 2015.
Descripteurs français
- KwdFr :
- Administration par voie topique, Comorbidité, Eczéma atopique (diagnostic), Eczéma atopique (traitement médicamenteux), Eczéma atopique (épidémiologie), Femelle, Hormones corticosurrénaliennes (effets indésirables), Hormones corticosurrénaliennes (usage thérapeutique), Humains, Immunosuppresseurs, Incidence, Indice de gravité médicale, Inhibiteurs de la calcineurine (effets indésirables), Inhibiteurs de la calcineurine (usage thérapeutique), Lymphome T cutané (diagnostic), Lymphome T cutané (épidémiologie), Mâle, Pronostic, Répartition par sexe, Répartition par âge, Tacrolimus (effets indésirables), Tacrolimus (usage thérapeutique), Tumeurs cutanées (diagnostic), Tumeurs cutanées (épidémiologie), Évaluation des risques.
- MESH :
- diagnostic : Eczéma atopique, Lymphome T cutané, Tumeurs cutanées.
- effets indésirables : Hormones corticosurrénaliennes, Inhibiteurs de la calcineurine, Tacrolimus.
- traitement médicamenteux : Eczéma atopique.
- usage thérapeutique : Hormones corticosurrénaliennes, Inhibiteurs de la calcineurine, Tacrolimus.
- épidémiologie : Eczéma atopique, Lymphome T cutané, Tumeurs cutanées.
- Administration par voie topique, Comorbidité, Femelle, Humains, Immunosuppresseurs, Incidence, Indice de gravité médicale, Mâle, Pronostic, Répartition par sexe, Répartition par âge, Évaluation des risques.
English descriptors
- KwdEn :
- Administration, Topical, Adrenal Cortex Hormones (adverse effects), Adrenal Cortex Hormones (therapeutic use), Age Distribution, Calcineurin Inhibitors (adverse effects), Calcineurin Inhibitors (therapeutic use), Comorbidity, Dermatitis, Atopic (diagnosis), Dermatitis, Atopic (drug therapy), Dermatitis, Atopic (epidemiology), Female, Humans, Immunosuppressive Agents, Incidence, Lymphoma, T-Cell, Cutaneous (diagnosis), Lymphoma, T-Cell, Cutaneous (epidemiology), Male, Prognosis, Risk Assessment, Severity of Illness Index, Sex Distribution, Skin Neoplasms (diagnosis), Skin Neoplasms (epidemiology), Tacrolimus (adverse effects), Tacrolimus (therapeutic use).
- MESH :
- chemical , adverse effects : Adrenal Cortex Hormones, Calcineurin Inhibitors, Tacrolimus.
- chemical , therapeutic use : Adrenal Cortex Hormones, Calcineurin Inhibitors, Tacrolimus.
- diagnosis : Dermatitis, Atopic, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms.
- drug therapy : Dermatitis, Atopic.
- epidemiology : Dermatitis, Atopic, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms.
- Administration, Topical, Age Distribution, Comorbidity, Female, Humans, Immunosuppressive Agents, Incidence, Male, Prognosis, Risk Assessment, Severity of Illness Index, Sex Distribution.
Abstract
There is controversy regarding a potential increased risk of lymphoma in patients with atopic dermatitis (AD).
DOI: 10.1016/j.jaad.2015.02.1116
PubMed: 25840730
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002C79
- to stream PubMed, to step Curation: 002C05
- to stream PubMed, to step Checkpoint: 002C05
Links to Exploration step
pubmed:25840730Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.</title><author><name sortKey="Legendre, Laureline" sort="Legendre, Laureline" uniqKey="Legendre L" first="Laureline" last="Legendre">Laureline Legendre</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Barnetche, Thomas" sort="Barnetche, Thomas" uniqKey="Barnetche T" first="Thomas" last="Barnetche">Thomas Barnetche</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Bordeaux University Hospital, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Mazereeuw Hautier, Juliette" sort="Mazereeuw Hautier, Juliette" uniqKey="Mazereeuw Hautier J" first="Juliette" last="Mazereeuw-Hautier">Juliette Mazereeuw-Hautier</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Meyer, Nicolas" sort="Meyer, Nicolas" uniqKey="Meyer N" first="Nicolas" last="Meyer">Nicolas Meyer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Murrell, Dedee" sort="Murrell, Dedee" uniqKey="Murrell D" first="Dedee" last="Murrell">Dedee Murrell</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University of New South Wales, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Dermatology, University of New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Paul, Carle" sort="Paul, Carle" uniqKey="Paul C" first="Carle" last="Paul">Carle Paul</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France. Electronic address: paul.c@chu-toulouse.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25840730</idno><idno type="pmid">25840730</idno><idno type="doi">10.1016/j.jaad.2015.02.1116</idno><idno type="wicri:Area/PubMed/Corpus">002C79</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C79</idno><idno type="wicri:Area/PubMed/Curation">002C05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C05</idno><idno type="wicri:Area/PubMed/Checkpoint">002C05</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C05</idno><idno type="wicri:Area/Ncbi/Merge">002414</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.</title><author><name sortKey="Legendre, Laureline" sort="Legendre, Laureline" uniqKey="Legendre L" first="Laureline" last="Legendre">Laureline Legendre</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Barnetche, Thomas" sort="Barnetche, Thomas" uniqKey="Barnetche T" first="Thomas" last="Barnetche">Thomas Barnetche</name><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Bordeaux University Hospital, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Mazereeuw Hautier, Juliette" sort="Mazereeuw Hautier, Juliette" uniqKey="Mazereeuw Hautier J" first="Juliette" last="Mazereeuw-Hautier">Juliette Mazereeuw-Hautier</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Meyer, Nicolas" sort="Meyer, Nicolas" uniqKey="Meyer N" first="Nicolas" last="Meyer">Nicolas Meyer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Murrell, Dedee" sort="Murrell, Dedee" uniqKey="Murrell D" first="Dedee" last="Murrell">Dedee Murrell</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University of New South Wales, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Dermatology, University of New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Paul, Carle" sort="Paul, Carle" uniqKey="Paul C" first="Carle" last="Paul">Carle Paul</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France. Electronic address: paul.c@chu-toulouse.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Paul Sabatier University, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of the American Academy of Dermatology</title><idno type="eISSN">1097-6787</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Topical</term><term>Adrenal Cortex Hormones (adverse effects)</term><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Age Distribution</term><term>Calcineurin Inhibitors (adverse effects)</term><term>Calcineurin Inhibitors (therapeutic use)</term><term>Comorbidity</term><term>Dermatitis, Atopic (diagnosis)</term><term>Dermatitis, Atopic (drug therapy)</term><term>Dermatitis, Atopic (epidemiology)</term><term>Female</term><term>Humans</term><term>Immunosuppressive Agents</term><term>Incidence</term><term>Lymphoma, T-Cell, Cutaneous (diagnosis)</term><term>Lymphoma, T-Cell, Cutaneous (epidemiology)</term><term>Male</term><term>Prognosis</term><term>Risk Assessment</term><term>Severity of Illness Index</term><term>Sex Distribution</term><term>Skin Neoplasms (diagnosis)</term><term>Skin Neoplasms (epidemiology)</term><term>Tacrolimus (adverse effects)</term><term>Tacrolimus (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie topique</term><term>Comorbidité</term><term>Eczéma atopique (diagnostic)</term><term>Eczéma atopique (traitement médicamenteux)</term><term>Eczéma atopique (épidémiologie)</term><term>Femelle</term><term>Hormones corticosurrénaliennes (effets indésirables)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains</term><term>Immunosuppresseurs</term><term>Incidence</term><term>Indice de gravité médicale</term><term>Inhibiteurs de la calcineurine (effets indésirables)</term><term>Inhibiteurs de la calcineurine (usage thérapeutique)</term><term>Lymphome T cutané (diagnostic)</term><term>Lymphome T cutané (épidémiologie)</term><term>Mâle</term><term>Pronostic</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Tacrolimus (effets indésirables)</term><term>Tacrolimus (usage thérapeutique)</term><term>Tumeurs cutanées (diagnostic)</term><term>Tumeurs cutanées (épidémiologie)</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Calcineurin Inhibitors</term><term>Tacrolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Calcineurin Inhibitors</term><term>Tacrolimus</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dermatitis, Atopic</term><term>Lymphoma, T-Cell, Cutaneous</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Eczéma atopique</term><term>Lymphome T cutané</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dermatitis, Atopic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hormones corticosurrénaliennes</term><term>Inhibiteurs de la calcineurine</term><term>Tacrolimus</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dermatitis, Atopic</term><term>Lymphoma, T-Cell, Cutaneous</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Eczéma atopique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hormones corticosurrénaliennes</term><term>Inhibiteurs de la calcineurine</term><term>Tacrolimus</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Eczéma atopique</term><term>Lymphome T cutané</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Topical</term><term>Age Distribution</term><term>Comorbidity</term><term>Female</term><term>Humans</term><term>Immunosuppressive Agents</term><term>Incidence</term><term>Male</term><term>Prognosis</term><term>Risk Assessment</term><term>Severity of Illness Index</term><term>Sex Distribution</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie topique</term><term>Comorbidité</term><term>Femelle</term><term>Humains</term><term>Immunosuppresseurs</term><term>Incidence</term><term>Indice de gravité médicale</term><term>Mâle</term><term>Pronostic</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is controversy regarding a potential increased risk of lymphoma in patients with atopic dermatitis (AD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25840730</PMID><DateCreated><Year>2015</Year><Month>05</Month><Day>18</Day></DateCreated><DateCompleted><Year>2015</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6787</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Dermatology</Title><ISOAbbreviation>J. Am. Acad. Dermatol.</ISOAbbreviation></Journal><ArticleTitle>Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.</ArticleTitle><Pagination><MedlinePgn>992-1002</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaad.2015.02.1116</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0190-9622(15)01356-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is controversy regarding a potential increased risk of lymphoma in patients with atopic dermatitis (AD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the risk of lymphoma and the role of topical treatments in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search and a separate meta-analysis were performed on case control and cohort studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 3979 articles retrieved, 24 references met the inclusion criteria. In cohort studies, the risk of lymphoma was slightly increased, with a relative risk (RR) of 1.43 (95% confidence interval [CI], 1.12-1.81). In case control studies, no significant increased risk of lymphoma was found, with an odds ratio (OR) of 1.18 (95% CI, 0.94-1.47). Severity of AD was a significant risk factor. Highly potent topical steroids were associated with an increased risk of lymphoma. For topical calcineurin inhibitors (TCIs), a significant association between tacrolimus and mostly skin lymphoma was found in 1 study.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Confusion between severe AD and cutaneous T-cell lymphoma may account for part of the increased risk of lymphoma in patients with AD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This systematic literature review shows a slightly increased risk of lymphoma in patients with AD. Severity of AD appears to be a significant risk factor. The role of topical steroids and TCIs is unlikely to be significant.</AbstractText><CopyrightInformation>Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Legendre</LastName><ForeName>Laureline</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnetche</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazereeuw-Hautier</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murrell</LastName><ForeName>Dedee</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Carle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Paul Sabatier University, Toulouse, France. Electronic address: paul.c@chu-toulouse.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Dermatol</MedlineTA><NlmUniqueID>7907132</NlmUniqueID><ISSNLinking>0190-9622</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber><NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065095" MajorTopicYN="N">Calcineurin Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003876" MajorTopicYN="N">Dermatitis, Atopic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016410" MajorTopicYN="N">Lymphoma, T-Cell, Cutaneous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atopic dermatitis</Keyword><Keyword MajorTopicYN="N">lymphoma</Keyword><Keyword MajorTopicYN="N">neoplasm</Keyword><Keyword MajorTopicYN="N">pimecrolimus</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">tacrolimus</Keyword><Keyword MajorTopicYN="N">topical corticosteroids</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>02</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25840730</ArticleId><ArticleId IdType="pii">S0190-9622(15)01356-0</ArticleId><ArticleId IdType="doi">10.1016/j.jaad.2015.02.1116</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Aquitaine</li><li>Midi-Pyrénées</li><li>Nouvelle-Aquitaine</li><li>Nouvelle-Galles du Sud</li><li>Occitanie (région administrative)</li></region><settlement><li>Bordeaux</li><li>Sydney</li><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Legendre, Laureline" sort="Legendre, Laureline" uniqKey="Legendre L" first="Laureline" last="Legendre">Laureline Legendre</name></region><name sortKey="Barnetche, Thomas" sort="Barnetche, Thomas" uniqKey="Barnetche T" first="Thomas" last="Barnetche">Thomas Barnetche</name><name sortKey="Mazereeuw Hautier, Juliette" sort="Mazereeuw Hautier, Juliette" uniqKey="Mazereeuw Hautier J" first="Juliette" last="Mazereeuw-Hautier">Juliette Mazereeuw-Hautier</name><name sortKey="Meyer, Nicolas" sort="Meyer, Nicolas" uniqKey="Meyer N" first="Nicolas" last="Meyer">Nicolas Meyer</name><name sortKey="Paul, Carle" sort="Paul, Carle" uniqKey="Paul C" first="Carle" last="Paul">Carle Paul</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Murrell, Dedee" sort="Murrell, Dedee" uniqKey="Murrell D" first="Dedee" last="Murrell">Dedee Murrell</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002414 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002414 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25840730
|texte= Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25840730" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |